Click HERE to view Webcast
This educational activity is specifically designed for hematologists, oncologists, internists and other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) involved in and/or interested in lymphoma, myeloma, and related plasma cell disorders and their management.
The annual Lymphoma & Myeloma meeting took place in New York City on October 18-20, 2007. Internationally known researchers and practitioners presented new and emerging therapeutic methods useful in treating the lymphomas, multiple myeloma, and plasma cell disorders. The Lymphoma & Myeloma 2007 conference was developed with the endeavor of producing an educational format that combines didactic sessions and panel discussions led by leaders in the field. This Webcast is taken directly from that meeting.
After completing this activity, the participant will be able to:
-
Review updates in the biology of myeloma, lymphoma, and related plasma cell disorders
- Utilize new diagnostic and prognostic indicators in myeloma, lymphoma, and related plasma cell disorders
- Identify the most important genetic and molecular abnormalities of myeloma and lymphoma cells
- Implement the latest first-line therapies in myeloma and lymphoma, and related plasma cell disorders
- Improve management of relapsed/refractory disease in myeloma and lymphoma
- Employ state-of-the-art therapies for both early and advanced lymphomas
- Implement evidence-based management strategies for the various types and stages of lymphoma, myeloma, and related plasma cell disorders
- Recognize available new drugs, as well as emerging therapies in the pipeline, for the treatment of myeloma, lymphoma, and related plasma cell disorders
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex®, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing generic names of several to ensure impartiality.
All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.
1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
| Myron S. Czuczman, MD |
BEN Program3 |
| James Dahlberg, PhD |
National Institute of Health1; Third Wave Technologies, Inc.2,4 |
| Robert O. Dillman, MD, FACP |
AstraZeneca Pharmaceuticals LP4, Bristol-Myers Squibb Company1,4, Johnson & Johnson4, NovaRx Corporation2, Pfizer Inc4, Schering-Plough Corporation4 |
| Rafael Fonseca, MD |
Pfizer Inc1 |
| Francine Foss, MD |
MERCK & CO., Inc.3; Therakos, Inc.2 |
| Richard R. Furman, MD |
BioCryst Pharmaceuticals, Inc.2 |
| Neil E. Kay, MD |
Hospira, Inc.1 |
| Emilio Montserrat, MD |
Amgen Inc.1, Roche Laboratories Inc.1,2, Münch Pharma2 |
| Paul G. Richardson, MD |
Johnson & Johnson3 |
| G. David Roodman, MD, PhD |
Amgen Inc.2; MERCK & CO., Inc.2; Multiple Myeloma Research Foundation1; National Institute of Health/ Institute of Arthritis and Musculoskeletal and Skin Diseases 1; VA Merit Review1 |
| John D. Shaughnessy Jr, PhD |
ZymoGenetics1,5 |
| Sonali M. Smith, MD |
Astellas Pharma Inc.2 |
| Donna Weber, MD |
MERCK & CO., Inc.1 |
| Anas Younes, MD |
Methylgene Inc.1, Seattle Genetics1 |
The following speakers have reported an affiliation with the supporters of this conference:
| Kenneth C. Anderson, MD, MA |
Celgene Corporation1,2,3; Millennium Pharmaceuticals, Inc.1,2,3; Novartis Pharmaceuticals Corporation1,2,3 |
| Bart Barlogie, MD, PhD |
Celgene Corporation1,3 ; Millennium Pharmaceuticals, Inc.1,3 |
| Asher A. Chanan-Khan, MD |
Celgene Corporation1,2,3; Millennium Pharmaceuticals, Inc.1,3 |
| Bruce D. Cheson, MD |
Biogen Idec Inc.3; Celgene Corporation2, Genentech BioOncology3 |
| Myron S. Czuczman, MD |
Biogen Idec Inc.1,5, Genentech BioOncology1 |
| Robert O. Dillman, MD, FACP |
Abbott Laboratories4, Bayer HealthCare Corporation5, Biogen Idec Inc.1,3,4, Genentech BioOncology3,4, GlaxoSmithKline4, Onyx Pharmaceuticals Inc.5 |
| Angela Dispenzieri, MD |
Celgene Corporation1 |
| Richard I. Fisher, MD |
Genentech BioOncology2,3,5 ; GlaxoSmithKline2,3,5 ; Millennium Pharmaceuticals, Inc.2,3,5 |
| Rafael Fonseca, MD |
Celgene Corporation2; Millennium Pharmaceuticals, Inc.2 |
| Francine Foss, MD |
Genentech BioOncology3, Gloucester Pharmaceuticals,
Inc.2 |
| Neil E. Kay, MD |
Bayer HealthCare Corporation1, Celgene Corporation2 |
| David G. Maloney, MD, PhD |
Biogen Idec Inc.2, Genentech BioOncology1,2, GlaxoSmithKline2, Gcam M 762 |
| Graham Mead, MD |
The Binding Site Ltd.5 |
| Ruben Niesvizky, MD |
Celgene Corporation3; Millennium Pharmaceuticals, Inc.3; Novartis Pharmaceuticals Corporation3; OrthoBiotech Products, L.P.3 |
| Carol S. Portlock, MD |
Genentech BioOncology3, Biogen Idec Inc.3 |
| Kanti Rai, MD |
BerlexLaboratories, Inc./Bayer HealthCare Corporation1 |
| S. Vincent Rajkumar, MD |
Celgene Corporation1 |
| Paul G. Richardson, MD |
Celgene Corporation3; Millenium Pharmaceuticals, Inc.3 |
| G. David Roodman, MD, PhD |
Celgene Corporation3; Millennium Pharmaceuticals, Inc.2,3; Novartis Pharmaceuticals Corporation2,3 |
| John D. Shaughnessy Jr, PhD |
Celgene Corporation1,2; Millennium Pharmaceuticals, Inc.1,5; Novartis Pharmaceuticals, Inc.1,5 |
| Sonali M. Smith, MD |
Biogen Idec Inc.2,3, Genentech BioOncology2,3 |
| David Vesole, MD, PhD, FACP |
Celgene Corporation3; Millennium Pharmaceuticals, Inc.3,4; Ortho Biotech Products, L.P.1,2,3 |
| Donna Weber, MD |
Celgene Corporation1,3; Millennium Pharmaceuticals, Inc.2,3 |
| Anas Younes, MD |
Genentech BioOncology1 |
The following speakers do not report any affiliation:
Raymond Alexanian, MD
Maurizio Bendandi, MD, PhD
Amy Chadburn, MD
Selina Chen-Kiang, PhD
Nicholas Chiorazzi, MD
Morton Coleman, MD
Raymond L. Comenzo, MD
Volker Diehl, MD
Scott Ely, MD
Randy D. Gascoyne, MD
Philip R. Greipp, MD
Sandra J. Horning, MD
Lale Kostakoglu, MD
Robert A. Kyle, MD
John P. Leonard, MD
Ari Melnick, MD
Saul A. Rosenberg, MD
Jia Ruan, MD, PhD
David J. Straus, MD
Wyndham H. Wilson, MD, PhD
Andrew D. Zelenetz, MD
Emanuele Zucca, MD
All materials are included with the permission of the authors.
All Imedex staff members who are in a position to control the content of this activity have no financial relationships with any commercial interests that are relevant to this activity.
Raymond Alexanian, MD
M. D. Anderson Cancer Center
Houston, Texas
Kenneth C. Anderson, MD, MA
Dana-Farber Cancer Institute
Boston, Massachusetts
Bart Barlogie, MD, PhD
University of Arkansas Medical Center
Little Rock, Arkansas
Maurizio Bendandi, MD, PhD
University Clinic, Department of Hematology
Pamplona, Spain
Amy Chadburn, MD
Weill Medical College Of Cornell University
New York, New York
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, New York
Selina Chen-Kiang, PhD
Weill Medical College Of Cornell University
New York, New York
Bruce D. Cheson, MD
Georgetown University Hospital
Washington, DC
Nicholas Chiorazzi, MD
North Shore - Long Island Jewish Research Institute
Manhasset, New York
Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
New York Presbyterian Hospitals
New York, New York
Raymond L. Comenzo, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Myron S. Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York
James Dahlberg, PhD
The University of Wisconsin Madison
Madison, Wisconsin
Volker Diehl, MD
University of Cologne
Cologne, Germany
Robert O. Dillman, MD, FACP
Hoag Cancer Center
Newport Beach, California
Angela Dispenzieri, MD
Mayo Clinic College of Medicine
Rochester, Minnesota
Scott Ely, MD
Weill Medical College of Cornell University
New York Presbyterian Hospitals
New York, New York
Richard I. Fisher, MD
University of Rochester Medical Center
Rochester, New York
|
Rafael Fonseca, MD
Mayo Clinic
Scottsdale, Arizona
Francine Foss, MD
Yale Medical Oncology
New Haven, Connecticut
Richard R. Furman, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
New York Presbyterian Hospitals
New York, New York
Randy D. Gascoyne, MD
British Columbia Cancer Center
Vancouver, British Columbia, Canada
Philip R. Greipp, MD
Mayo Clinic College of Medicine
Rochester, Minnesota
Sandra J. Horning, MD
Stanford University Medical Center
Stanford, California
Neil E. Kay, MD
Mayo Clinic
Rochester, Minnesota
Lale Kostakoglu, MD
Mount Sinai Medical Center
New York, New York
Robert A. Kyle, MD
Mayo Clinic
Rochester, Minnesota
John P. Leonard, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
New York Presbyterian Hospitals
New York, New York
David G. Maloney, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, Washington
Graham Mead, MD
The Binding Site Ltd.
Birmingham, United Kingdom
Ari Melnick, MD
Albert Einstein College of Medicine
Bronx, New York
Emilio Montserrat, MD
University of Barcelona
Barcelona, Spain
Ruben Niesvizky, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
New York Presbyterian Hospitals
New York, New York
Carol S. Portlock, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
|
Kanti Rai, MD
Long Island Jewish Medical Center
New Hyde Park, New York
S. Vincent Rajkumar, MD
Mayo Medical School
Rochester, Minnesota
Paul G. Richardson, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
G. David Roodman, MD, PhD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Saul A. Rosenberg, MD
Stanford Comprehensive Cancer Center
Stanford, California
Jia Ruan, MD, PhD
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York, New York
John D. Shaughnessy Jr, PhD
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Sonali M. Smith, MD
University of Chicago
Division of Biological Sciences
Chicago, Illinois
David J. Straus, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
David Vesole, MD, PhD, FACP
St. Vincent's Comprehensive Cancer Center
New York, New York
Donna Weber, MD
M. D. Anderson Cancer Center
Houston, Texas
Wyndham H. Wilson, MD, PhD
National Cancer Institute
Bethesda, Maryland
Anas Younes, MD
M. D. Anderson Cancer Center
Houston, Texas
Andrew D. Zelenetz, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Emanuele Zucca, MD
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland |
This activity is sponsored by Imedex, LLC.
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum of 18.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.
For questions regarding the accreditation of this activity, please contact
Imedex
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751-7334
Email: enduring@imedex.com
This Webcast may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
The opinions expressed in this email case discussion are the opinions of the authors and do not necessarily reflect the opinions of Imedex, LLC.
The following companies have provided unrestricted educational grants in support of this activity: Abbott Laboratories; Allos Therapeutics, Inc.; Bayer HealthCare Corporation; Onyx Pharmaceuticals Inc.; Biogen Idec Inc.; Celgene Corporation; Cephalon, Inc.; Favrille, Inc.; Genentech BioOncology; Genzyme Corporation; GlaxoSmithKline; Gloucester Pharmaceuticals; Johnson & Johnson; Eli Lily and Company; MedImmune Inc.; Millennium Pharmaceuticals Inc.; Novartis Pharmaceuticals Corporation; Ortho Biotech Products, L.P.; Proteolix, Inc.; Sigma -Tau; and The Binding Site Ltd.
Click HERE to view Webcast
| System Requirements: |
 is required for proper viewing. Click here to download
- Pentium 500 processor or greater
- Windows 98/NT/2000/XP or Mac OS 9/X
- Microsoft Internet Explorer 5.5 or later
(Firefox browser currently not supported)
- 128 MB of RAM
- Monitor settings: High color at 800 x 600 pixels
- Sound card and speakers
Audio troubleshooting
For general troubleshooting concerning audio or video playback issues consult the following Web link: http://support.microsoft.com/kb/306317.
|
|
